Table Info

Table 1.

RNA expression of angiogenesis factors

Genes identity	SCLC26A	BHGc7	BHGc10	BHGc16	BHGc26	UHGc5
Angiopoietin-2 ENSG00000091879	4.67	192.75	16	35	204	7.74
FIII/TF ENSG00000117525	17.12	71.74	50	214	152	57.59
FGF basic ENSG00000138685	38.91	42.03	28	92	20	4.67
HGF ENSG00000019991	0	0	2	4	0	0
Thrombospondin 1 ENSG00000137801	123.35	498.55	7	23	33	6.61
uPA ENSG00000122861	63.42	21.01	6	4	20	0
VEGF ENSG00000112715	2,240.47	3,188.41	3,791	2,019	3,580	1,498.05

Declarations

Author contributions

MH: Conceptualization. CN: Conceptualization, Funding acquisition. GH: Conceptualization, Writing—original draft. BB and EU: Formal analysis. BR: Investigation, Formal analysis, Writing—original draft. LK: Investigation. AP: Formal analysis, Writing—original draft. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Blood collection and generation of cell lines are approved by the Ethics Committee of the Medical University of Vienna, Vienna, Austria (366/2003) and comply with the Declaration of Helsinki.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This research was partially funded by the Medical Scientific Fund of the Mayor of the City of Vienna [19202]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;10:380. [DOI] [PubMed] [PMC]

van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012;119:924–32. [DOI] [PubMed]

Rak J, Milsom C, Magnus N, Yu J. Tissue factor in tumour progression. Best Pract Res Clin Haematol. 2009;22:71–83. [DOI] [PubMed]

Gerotziafas GT, Galea V, Mbemba E, Khaterchi A, Sassi M, Baccouche H, et al. Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thromb Res. 2012;129:779–86. [DOI] [PubMed]

Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005;103:994–9. [DOI] [PubMed]

Lima LG, Oliveira AS, Campos LC, Bonamino M, Chammas R, Werneck C, et al. Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles. Thromb Haemost. 2011;106:712–23. [DOI] [PubMed]

Micalizzi DS, Maheswaran S, Haber DA. A conduit to metastasis: circulating tumor cell biology. Genes Dev. 2017;31:1827–40. [DOI] [PubMed] [PMC]

Bourcy M, Suarez-Carmona M, Lambert J, Francart ME, Schroeder H, Delierneux C, et al. Tissue factor induced by epithelial-mesenchymal transition triggers a procoagulant state that drives metastasis of circulating tumor cells. Cancer Res. 2016;76:4270–82. [DOI] [PubMed]

Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer—clinical applications. Nat Rev Clin Oncol. 2010;7:693–701. [DOI] [PubMed]

10.

Klameth L, Rath B, Hochmaier M, Moser D, Redl M, Mungenast F, et al. Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance. Sci Rep. 2017;7:5337. [DOI] [PubMed] [PMC]

11.

Hamilton G, Hochmair M, Rath B, Klameth L, Zeillinger R. Small cell lung cancer: circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype. Cell Adh Migr. 2016;10:360–7. [DOI] [PubMed] [PMC]

12.

Hamilton G, Rath B, Klameth L, Hochmair MJ. Small cell lung cancer: recruitment of macrophages by circulating tumor cells. Oncoimmunology. 2015;5:e1093277. [DOI] [PubMed] [PMC]

13.

Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 2007;5:246–54. [DOI] [PubMed]

14.

Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood. 1990;76:731–6. [DOI] [PubMed]

15.

Nitori N, Ino Y, Nakanishi Y, Yamada T, Honda K, Yanagihara K, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2005;11:2531–9. [DOI] [PubMed]

16.

Patry G, Hovington H, Larue H, Harel F, Fradet Y, Lacombe L. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer. Int J Cancer. 2008;122:1592–7. [DOI] [PubMed]

17.

Gil-Bernabé AM, Lucotti S, Muschel RJ. Coagulation and metastasis: what does the experimental literature tell us? Br J Haematol. 2013;162:433–41. [DOI] [PubMed]

18.

Gezelius E, Flou Kristensen A, Bendahl PO, Hisada Y, Risom Kristensen S, Ek L, et al. Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: a sub-study of RASTEN - a randomized trial with low molecular weight heparin. PLoS One. 2018;13:e0207387. [DOI] [PubMed] [PMC]

19.

Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer. 1990;65:481–5. [DOI] [PubMed]

20.

Hahn N, Heiden M, Seitz R, Salge-Bartels U. Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion. J Cancer Res Clin Oncol. 2012;138:695–703. [DOI] [PubMed]

21.

Keller T, Salge U, König H, Dodt J, Heiden M, Seitz R. Tissue factor is the only activator of coagulation in cultured human lung cancer cells. Lung Cancer. 2001;31:171–9. [DOI] [PubMed]

22.

Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, et al. Perspective on circulating tumor cell clusters: why it takes a village to metastasize. Cancer Res. 2018;78:845–52. [DOI] [PubMed]

23.

Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110–22. [DOI] [PubMed] [PMC]

24.

Regina S, Rollin J, Bléchet C, Iochmann S, Reverdiau P, Gruel Y. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol. 2008;3:689–97. [DOI] [PubMed]

25.

Laroche M, Peyrafitte M, Vissac AM, Amiral J. The multiple faces of tissue factor measured with laboratory assays. HYPHEN BioMed [Internet]. 2011 [cited 2022 Aug 8]. Available from: https://www.aniara.com/mm5/PDFs/Literature/HBM_Mult-Faces-Tissue-Factor.pdf

26.

Mackman N, Hisada Y, Archibald SJ. Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer: comment by Mackman et al. Cancer Sci. 2022;113:1885–7. [DOI] [PubMed] [PMC]

27.

Albo D, Rothman VL, Roberts DD, Tuszynski GP. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer. 2000;83:298–306. [DOI] [PubMed] [PMC]

28.

Montanino A, Manzo A, Carillio G, Palumbo G, Esposito G, Sforza V, et al. Angiogenesis inhibitors in small cell lung cancer. Front Oncol. 2021;11:655316. [DOI] [PubMed] [PMC]

29.

Semenova EA, Nagel R, Berns A. Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev. 2015;29:1447–62. [DOI] [PubMed] [PMC]

30.

Wang F, Xu P, Xie KC, Chen XF, Li CY, Huang Q. Effects of tumor microenviromental factors on VEGF expression. Biomed Rep. 2013;1:539–44. [DOI] [PubMed] [PMC]

31.

Zhang M, Wu S, Hu C. Do lung cancer patients require routine anticoagulation treatment? A meta-analysis. J Int Med Res. 2020;48:300060519896919. [DOI] [PubMed] [PMC]